The trial aims to investigate the safety and preliminary efficacy of MOR202 in patients with relapsed or refractory multiple myeloma.
In the trial, the patients with relapsed or refractory multiple myeloma are expected to be treated with different doses of the HuCAL-derived antibody MOR202.
MorphoSys chief development officer Arndt Schottelius said they will evaluate MOR202 both as a monotherapy and in combination with standard therapy.
"In total, this is our third proprietary antibody program in clinical trials, following MOR103 in rheumatoid arthritis and MOR208 in chronic lymphocytic leukemia," Schottelius said.